Saudi Hospital Offers Effective Weight Loss Injections for Type 2 Diabetes Patients: Discover the Breakthrough Treatment
Dallah Hospital AlNakheel in Riyadh, Saudi Arabia, is providing groundbreaking treatment options for individuals with type 2 diabetes and obesity. The Internal Medicine Department at the hospital offers safe and effective treatment plans using advanced injectable drugs, promising hope for those seeking to manage their conditions and shed excess weight.
Under the supervision of specialized consultants and highly qualified nurses, injections are administered to ensure the treatments are effective. These injections, also known as Weight Loss Injections, have gained widespread usage after being approved by relevant international authorities based on recent clinical trials.
Dr. Abdullah bin Rkhyes, a Family Medicine consultant at Dallah Hospital AlNakheel, explains that Ozempic and Mounjaro are the most commonly used injections to manage type 2 diabetes with obesity. Both injections have demonstrated significant results, with Mounjaro showing particular effectiveness in aiding weight loss.
Dr. Abdullah bin Rkhyes addresses the potential side effects of using diabetes treatment injections for weight loss. He notes that individuals without type 2 diabetes who use these injections for weight loss may experience hypoglycemia with high dosages. Additionally, some patients may experience nausea and a desire to vomit when starting this treatment, although this is observed in only a small percentage of patients.
The medical dosage used for these injections differs between treating type 2 diabetes and promoting weight loss in cases of morbid obesity. Moreover, the age range for individuals eligible for these injections has recently expanded to include those aged 12 and above, with previous approval limited to those aged 18 and older. The Family Medicine and Chronic Diseases consultants within the Internal Medicine Department supervise the administration of these injections at Dallah Hospital AlNakheel to ensure their safe and effective usage.
Dr. Abdullah bin Rkhyes emphasizes that these injections can be utilized for any patient with a BMI above 27 who also has accompanying chronic conditions like type 2 diabetes, high blood pressure, or high cholesterol. In the case of Ozempic, it can be used for any patient with a BMI above 30. The injections of Ozempic and Mounjaro are administered just below the skin in areas such as the abdomen, thigh, or upper arm.
Dallah Health Group, consisting of six leading healthcare facilities, including Dallah Hospital AlNakheel, serves over 1.5 million patients annually across Saudi Arabia. With a dedicated workforce of more than 3,000 employees, the group ensures the delivery of the highest standards of healthcare in the Kingdom.
In conclusion, the Internal Medicine Department at Dallah Hospital AlNakheel in Riyadh provides state-of-the-art weight loss injections for patients with type 2 diabetes and obesity. Through the use of advanced injectable drugs, under the supervision of specialized consultants and highly qualified nurses, individuals can benefit from these effective treatments. Furthermore, the expansion of eligibility criteria for these injections showcases the hospital’s commitment to promoting holistic healthcare in Saudi Arabia.
